Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells $86,927.90 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Free Report) Director Molly Harper sold 5,333 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $16.30, for a total transaction of $86,927.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock traded up $0.27 during trading on Wednesday, hitting $16.31. The stock had a trading volume of 1,008,077 shares, compared to its average volume of 1,360,698. The business has a fifty day moving average of $15.66 and a two-hundred day moving average of $15.20. The firm has a market cap of $1.93 billion, a P/E ratio of 30.11, a PEG ratio of 1.37 and a beta of 0.73. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $11.48 and a fifty-two week high of $17.50.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.31. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. The firm had revenue of $98.51 million during the quarter, compared to the consensus estimate of $97.24 million. As a group, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.78 earnings per share for the current year.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Ameritas Investment Partners Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 720 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 819 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Catalyst Pharmaceuticals by 4.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 1,290 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 9.7% in the first quarter. Mutual of America Capital Management LLC now owns 19,241 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 1,701 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Catalyst Pharmaceuticals by 15.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 12,960 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 1,719 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the topic of several recent research reports. Bank of America assumed coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 7th. They set a “buy” rating and a $23.00 target price on the stock. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Catalyst Pharmaceuticals in a report on Monday. Citigroup started coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price objective for the company. Finally, StockNews.com cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $26.71.

Read Our Latest Stock Report on CPRX

About Catalyst Pharmaceuticals

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.